【ChiCTR2500114608】Implementation of biomimetic 3D bioprinting technology in selecting optimal regimens as adjuvant therapy to prevent hepatocellular carcinoma recurrence after liver resection or ablation: a feasibility study
ChiCTR2500114608
正在进行
/
/
/
2025-12-15
/
/
Liver cancer
Implementation of biomimetic 3D bioprinting technology in selecting optimal regimens as adjuvant therapy to prevent hepatocellular carcinoma recurrence after liver resection or ablation: a feasibility study
Implementation of biomimetic 3D bioprinting technology in selecting optimal regimens as adjuvant therapy to prevent hepatocellular carcinoma recurrence after liver resection or ablation: a feasibility study
To evaluate the efficacy of biomimetic 3D bioprinting technology in guiding the selection of optimal adjuvant treatment regimens to prevent hepatocellular carcinoma (HCC) recurrence after curative liver resection.
病例研究
其它
None
/
None
/
20
/
2025-12-15
2030-12-31
/
1. Age >= 18 years at the time of screening; 2.Diagnosis of HCC; 3.Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; 4. With or without prior locoregional therapy such as transarterial chemoembolisation (TACE), radiofrequency ablation (RFA), and stereotactic body radiation therapy (SBRT) before surgery; 5.Meet any item indicating higher risk of tumour recurrence: any tumour size >= 5cm, number of tumour >= 3, presence of microvascular or marcovascular invasion, or poor tumour differentiation; 6.No prior systemic therapy for HCC; 7. No other active malignancies within 5 years, except malignancies with a negligible risk of metastasis or death (eg. 5-year overall survival rate > 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localised prostate cancer, ductal carcinoma in situ, or stage I uterine cancer; 8. Willing and able to provide written informed consent for the collection and usage of biological samples.；
请登录查看1.Non-HCC diagnosis, including fibrolamellar HCC, sarcomatoid HCC, mixed HCC cholangiocarcinoma etc; 2.Fail to give consent or refusal to take part in the study; 3.Child-Pugh class C liver cirrhosis; 4.Receipt of any prior systemic therapy for HCC.；
请登录查看Department of Surgery, The University of Hong Kong
/
Department of Surgery, The University of Hong Kong的其他临床试验
Department of Surgery, The University of Hong Kong的其他临床试验
- Implementation of biomimetic 3D bioprinting technology in selecting optimal regimens as adjuvant therapy to prevent hepatocellular carcinoma recurrence after liver resection or ablation: a feasibility study
- 黏合式骨導助聽器對傳導性弱聽人士的聽力效益及用者滿意狀況
- 建立寬頻聲阻抗於中國人耳朵的標準數據
- 鼻敏感患者的鼻尖峰吸氣流量與睡眠質素之關係
- 肌電圖和神經傳導試驗研究頭頸部癌症患者的吞嚥模式
最新临床资讯
-
飞眸医疗首例人体临床试验（FIH）成功开展，国产飞秒屈光设备竞逐540亿屈光市场
动脉网-最新2026-09-10
-
和铂医药：超长效靶向TSLP抗体哮喘二期临床取得阳性结果，三期临床已启动
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
动脉网-最新2026-09-09
-
药明康德2026-09-09
-
一度医药2026-09-08
-
阿斯利康中国2026-09-08
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-09-10
-
2026-09-09
-
2026-09-08
-
摩熵咨询 20 5
-
摩熵咨询 20 8
-
摩熵咨询 34 43
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
-
颁布机构：国家药品审评中心（CDE） 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-09-10
-
2026-09-10
-
2026-09-10
-
摩熵咨询 35 60
-
摩熵咨询 28 52
-
摩熵咨询 34 37
-
颁布机构：国家市场监督管理总局 2026-08-10
-
颁布机构：国家市场监督管理总局 2026-05-29
-
颁布机构：国家市场监督管理总局 2026-05-29